Potential Savara Inc. (NASDAQ:SVRA) shareholders may wish to note that the Independent Director, David Ramsay, recently bought US$288k worth of stock, paying US$2.88 for each share. Although the purchase only increased their holding by 4.5%, it is still a solid purchase in our view.
View our latest analysis for Savara
Savara Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the Chairman & CEO, Matthew Pauls, sold US$396k worth of shares at a price of US$4.71 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$3.13. So it is hard to draw any strong conclusion from it.
All up, insiders sold more shares in Savara than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Savara
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Savara insiders own 1.9% of the company, worth about US$9.4m. Whilst better than nothing, we're not overly impressed by these holdings.
So What Does This Data Suggest About Savara Insiders?
The recent insider purchase is heartening. On the other hand the transaction history, over the last year, isn't so positive. We're not thrilled with the relatively low insider ownership and the longer term transaction history. But we like the recent purchasing. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Savara. Be aware that Savara is showing 3 warning signs in our investment analysis, and 1 of those is significant...
But note: Savara may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:SVRA
Savara
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
Flawless balance sheet low.